Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Anacor's AN3365 novel systemic antibiotic achieves proof of concept

Anacor Pharmaceuticals today announced that a Joint Research Committee, composed of both GlaxoSmithKline (GSK) and Anacor employees, has determined that AN3365, a novel systemic antibiotic derived from Anacor's boron chemistry platform, has achieved proof of concept as defined under the collaboration agreement between GSK and Anacor.

15 Jun 2010

Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced

Anacor Pharmaceuticals today announced positive clinical trial results for its lead phosphodiesterase-4 inhibitor, AN2728, a novel topical anti-inflammatory compound derived from Anacor's boron chemistry platform. These results were obtained from a multi-center, Phase 2b, randomized, double-blind, dose-ranging, bilateral trial comparing AN2728 ointment, 0.5% and 2.0%, applied once or twice daily, to vehicle in 145 patients with mild-to-moderate plaque-type psoriasis.

15 Jun 2010

SIRS-Lab, Analytik Jena partner in molecular sepsis diagnostics

SIRS-Lab GmbH and Analytik Jena AG, also based in Jena, will be strengthened by working together in the field of molecular sepsis diagnostics. As part of this cooperation, Analytik Jena subsidiary AJ Innuscreen GmbH will provide the partner with a platform for automated isolation of nucleic acids with the associated reagent system worth almost half a million euro.

15 Jun 2010

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

Oragenics, Inc., a biopharmaceutical company, announced today that the National Science Foundation has awarded the Company an additional $500,000 in funds to support the previously awarded SBIR Phase II grant for the Company's DPOLT Lantibiotic Synthesis Platform.

14 Jun 2010

PolyMedix awarded $150,000 grant to support development of antimicrobial sutures to reduce SSIs

A new discovery may help curb surgical site infections through the use of a novel antibiotic agent that can be incorporated into sutures. SSIs are the third most common hospital-acquired infection and may be associated with severe morbidity and mortality. Since more than 60% of SSIs occur in the area of the incision, the use of sutures coated with an antibacterial agent called PolyCides, created by Radnor, PA-based PolyMedix Inc., may reduce infection rates.

14 Jun 2010

Olfactory function tests could help in treating patient in early stages of PD

A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease, in which motor symptoms only become evident at a later stage of the disease, a German scientist will tell the annual conference of the European Society of Human Genetics today (Saturday).

14 Jun 2010

Anti-infectives could circumvent the problem of antibiotic resistance

For a successful infection, bacteria must outwit the immune system of the host. To this aim, they deliver so-called virulence factors through a transport channel located in the bacterial membrane.

14 Jun 2010

Otonomy completes $10 million Series A financing with Avalon Ventures

Otonomy, Inc. announced today that it has completed a $10 million Series A financing with Avalon Ventures. Proceeds from the financing will be used to support the ongoing clinical trial for OTO-104 in Meniere's disease, initiate IND-enabling studies for OTO-203, and continue early-stage development of a third program.

11 Jun 2010

Cubist to oppose Teva’s attempt to add new defense in patent infringement litigation

Cubist Pharmaceuticals, Inc. today announced that it will oppose a motion filed by the Teva defendants to amend their answer to add a new defense in the patent litigation between Cubist and Teva pending in the US District Court for the District of Delaware. A motion for leave to amend the answer is a request to be permitted to add a new allegation. The Teva defendants seek leave to amend their answer to allege that US Patent Nos. 6,468,967 and 6,852,689 are unenforceable due to inequitable conduct.

11 Jun 2010

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

A team of researchers at Childrens Hospital Los Angeles (CHLA), along with colleagues from the Keck School of Medicine of the University of Southern California and the Universite Auvergne, France, have discovered an important role for a small, naturally occurring protein called interleukin-10 (IL-10) in removing bacteria from the blood of infected mice and reversing damage to the brain.

11 Jun 2010

Extensive usage of antibiotic linezolid associated with ICU outbreak of LRSA

An outbreak of infection due to linezolid and methicillin-resistant Staphylococcus aureus (LRSA) in 12 intensive care unit patients in Spain was associated with transmission within the hospital and extensive usage of the antibiotic linezolid, often used for the treatment of serious infections, with reductions in linezolid use and infection-control measures associated with resolution of the outbreak, according to a study in the June 9 issue of JAMA.

10 Jun 2010

Texas Tech signs worldwide license agreement for metallo-beta-lactamase inhibitors with RI Scientific

Officials at Texas Tech University System's Office of Technology Commercialization announced Wednesday (June 9) the signing of an exclusive worldwide license agreement for a chemical additive called an aptamer that makes certain existing antibiotics viable against antibiotic-resistant bacteria.

10 Jun 2010

Clinical guidelines for UC emergency medicine physicians

Though guidelines for best treatment practices are common, they are only partially effective without standardized, routine exposure to them in clinical practice, according to a study conducted by University of Cincinnati emergency medicine researchers.

9 Jun 2010

Inquiry into the hospital acquired killer bug starts

A Second World War veteran John Boyle died of Clostridium difficile infection after being admitted to hospital for the first time at the age of 90. He was diagnosed with the infection on January 25 this year and succumbed to it two weeks later. He was one of 18 patients to die at a Scottish hospital when the outbreak of this hospital-acquired infection was reported.

8 Jun 2010

Xenex Healthcare Services announces commercial launch of pulsed xenon room disinfection system

Xenex Healthcare Services LLC, which specializes in developing disinfection technology for healthcare facilities, today announced the commercial launch of its pulsed xenon room disinfection system and the conclusion of the Xenex system's successful trial at a leading U.S. cancer center. The Xenex system, which is now available, is the fastest, safest, and most effective method for the advanced cleaning of hospital rooms in the world today, quickly destroying all major classes of microorganisms (including viruses, bacteria and bacterial spores) without contact or chemicals.

8 Jun 2010

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

Cubist Pharmaceuticals, Inc. today announced that the U.S. District Court for the District of Delaware issued a claim construction order in the litigation between Cubist and Teva.

8 Jun 2010

FDA grants Cepheid marketing clearance for Xpert SA Nasal Complete molecular test

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® SA Nasal Complete, the first and only molecular test designed for the simultaneous detection and differentiation of both Staphylococcus aureus (SA) and Methicillin-resistant Staphylococcus aureus (MRSA) colonization in less than one hour. The test runs on Cepheid's GeneXpert® System, the world's leading molecular platform for accuracy, speed, and ease-of-use.

8 Jun 2010

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix Pharmaceuticals, Ltd. today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

8 Jun 2010

Acella Pharmaceuticals signs license agreement for marketing rights to generic broad-spectrum antibiotic

Acella Pharmaceuticals has signed a licensing agreement for the U.S. marketing rights to a generic version of an intravenous administered broad-spectrum antibiotic.

8 Jun 2010

Researchers develop biosensors to monitor concentration of c-di-GMP within single living bacteria cells

Some species of bacteria perform an amazing reproductive feat. When the single-celled organism splits in two, the daughter cell - the swarmer - inherits a propeller to swim freely. The mother cell builds a stalk to cling to surfaces.

4 Jun 2010

Antibiotic News and Research

Further Reading

Anacor's AN3365 novel systemic antibiotic achieves proof of concept

Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced

SIRS-Lab, Analytik Jena partner in molecular sepsis diagnostics

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

PolyMedix awarded $150,000 grant to support development of antimicrobial sutures to reduce SSIs

Olfactory function tests could help in treating patient in early stages of PD

Anti-infectives could circumvent the problem of antibiotic resistance

Otonomy completes $10 million Series A financing with Avalon Ventures

Cubist to oppose Teva’s attempt to add new defense in patent infringement litigation

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

Extensive usage of antibiotic linezolid associated with ICU outbreak of LRSA

Texas Tech signs worldwide license agreement for metallo-beta-lactamase inhibitors with RI Scientific

Clinical guidelines for UC emergency medicine physicians

Inquiry into the hospital acquired killer bug starts

Xenex Healthcare Services announces commercial launch of pulsed xenon room disinfection system

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

FDA grants Cepheid marketing clearance for Xpert SA Nasal Complete molecular test

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Acella Pharmaceuticals signs license agreement for marketing rights to generic broad-spectrum antibiotic

Researchers develop biosensors to monitor concentration of c-di-GMP within single living bacteria cells

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News